

Figure 4. Plots of geographic atrophy (GA) growth in 7 participants with bilateral GA. Participants in the top row had fellow eyes that had received anti-vascular endothelial growth factor (VEGF) treatment for neovascular disease during and/or before entering the study. Participants in the bottom row had fellow eyes that were non-neovascular and therefore never received anti-VEGF.

